ArticleMedicine2026
Analytical method development and validation of a serum LC-MS/MS assay for 2 emerging synthetic cannabinoids: 5F-MDMB-PICA and MDMB-4en-PINACA.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to develop and validate a highly sensitive and reproducible liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous determination of 5F-MDMB-PICA and MDMB-4en-PINACA in human serum, ensuring suitability for both forensic and clinical toxicology applications.
methodsDrug-free serum samples were fortified with target analytes, extracted through solid-phase extraction, and analyzed using a triple-quadrupole LC-MS/MS system (Shimadzu LCMS-8045) equipped with a biphenyl column. Calibration was established within 1-100 ng/mL, and validation parameters - linearity, sensitivity, accuracy, and precision - were assessed according to international guidelines.
resultsThe calibration curves displayed excellent linearity (r2 = 0.999) for both analytes. The limits of detection were 0.113 ng/mL for 5F-MDMB-PICA and 0.145 ng/mL for MDMB-4en-PINACA, with limits of quantification of 0.339 ng/mL and 0.435 ng/mL, respectively. Recovery rates at 10 and 50 ng/mL ranged from 77.7% to 96.4%, while intra and inter-day precision (relative standard deviation %) remained below 15%.
conclusionThe validated method provides reliable quantification of 5F-MDMB-PICA and MDMB-4en-PINACA in human serum. The observed linearity, sensitivity, recovery, and precision support its applicability for routine forensic toxicology analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.